Fig. 4.

ITGA5-antibodies block mutant p53-driven pro-metastatic properties. a Western blot for p53, ENTPD5, and ITGA5. MIA PaCa-2 pIND-ENTPD5 cells (with tet-inducible expression of ENTPD5) were induced with doxycycline (+ tet), transfected with p53 siRNA (p53si) and treated with ITGA5-blocking antibody (α5) as indicated. β-actin is shown as a loading control. b Adhesion kinetics of MIA PaCa-2 pIND-ENTPD5 cells on FN. Cells were induced with doxycycline (+ tet) as indicated, transfected with p53 siRNA (p53si), and treated with ITGA5-blocking antibody (α5). c-d Invasion of MIA PaCa-2 pIND-ENTPD5 cells through FN-containing collagen gels following depletion of p53 and/or treatment with ITGA5-blocking antibody in the absence or presence of tet (ENTPD5 overexpression). c Representative images of crystal violet-stained transwell inserts. d Quantification of invasion assays. All graphs show the mean ± SD of n = 3 biological replicates. Statistical significance was tested using two-way ANOVA followed by Dunnett’s multiple comparisons test: ****, p < 0.0001; ns, not significant